Pauline Latham OBE MP has welcomed news that Government spending on the Cancer Drugs Fund will increase by £60 million to £340 million. In other news, it was also announced that the drug Abraxane will be retained on the list of approved treatments on the Cancer Drugs Fund for the near future.
In December, Mrs Latham along with a number of other MPs submitted a petition to Number 10 Downing Street to prevent Abraxane’s removal from the Cancer Drugs Fund. The petition has 2,165 signatories, consisting of patients and clinicians alike.
Pancreatic cancer is among the most aggressive forms of the disease, with the lowest 5 year survival rate of any of the 21 most common cancers, standing at just 4%. There are also very few treatments to fight it
Mrs Latham, MP for Mid Derbyshire said:
“The Cancer Drugs Fund offers hope to those who are battling cancer, and I am delighted that spending has increased. This would not only mean an increase in the quality and range of drugs available, but better outcomes for patients.
The news about Abraxane is also hopeful, and I am pleased that in the short term at least, many more people will benefit from the precious two months it adds to their lives. However, it is clear that the battle to keep this drug on the Cancer Drugs Fund is not over, and my colleagues and I will continue to fight for the interests of pancreatic cancer patients.”